TerminatedPhase 2NCT04639024

ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN

Studying Myeloproliferative neoplasm

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Gwynn Long, M.D.
Principal Investigator
Gwynn Long, M.D.
Professor of Medicine
Intervention
ADCT-301(drug)
Enrollment
3 enrolled
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (1)

Collaborators

ADC Therapeutics S.A.

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04639024 on ClinicalTrials.gov

Other trials for Myeloproliferative neoplasm

Additional recruiting or active studies for the same condition.

See all trials for Myeloproliferative neoplasm

← Back to all trials